Best Biopsy Doctors in China — TOP 16

Dr. Li Ping, M.D., Ph.D., is Chief Physician and Professor in the Department of Hematology at Shanghai Tongji Hospital, Tongji University School of Medicine. She supervises doctoral and master's students and is an expert in hematologic malignancies.

She earned a Doctor of Medical Science from Nagoya University and completed postdoctoral research. She specializes in diagnosing and treating blood cancers. Her focus includes lymphoid malignancies—leukemias, lymphomas, and multiple myeloma. She treats patients with chemotherapy, hematopoietic stem cell transplantation, targeted therapy, and immunotherapy.

She is a pioneer in China in full-cycle CAR-T therapy for relapsed or refractory blood cancers. She leads and participates in national and international clinical trials. She serves on committees of professional societies, including the China Anti-Cancer Association. She also publishes and trains hematologists.

Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.

Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.

Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.

He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).

He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.

Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Dr. Ding Yi is the Associate Chief Physician in Hematology at Shanghai Tongji Hospital. She is also the acting deputy director of the Blood Transfusion Department. She holds a Master of Medicine from Tongji University. She serves on the Youth Committee of the Shanghai Society of Hematology.

She is skilled in diagnosing and treating leukemia, lymphoma, and myeloma. She offers hematopoietic and umbilical cord blood stem cell therapies. She specializes in acute leukemia. She developed sequential treatment protocols. She participated in research that won the Second Prize of the Shanghai Science and Technology Progress Award. She has published more than 10 papers.

Dr. Wu Sufang is a Professor, Chief Physician, and Director of Obstetrics and Gynecology at a tertiary hospital in China. She has over 30 years of experience in gynecologic oncology. She trained under Academician Martin and completed postdoctoral research at MD Anderson Cancer Center.

Her surgical expertise includes radical hysterectomy, ovarian cytoreduction, endometrial cancer staging, and complex pelvic and para-aortic lymphadenectomy. She also performs fertility-sparing and minimally invasive procedures. She tailors chemotherapy, radiotherapy, and targeted therapy to each patient to improve survival and quality of life.

She is the principal investigator of four NSFC projects. She has published over 50 SCI papers, most as first or corresponding author. She serves on the standing committee of the Gynecologic Oncology Branch of the Chinese Medical Association and as an expert for the Chinese Anti-Cancer Association. She is an invited speaker and an award-winning mentor.

Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.

• Highly proficient in IMRT, VMAT, and SBRT for lung and esophageal cancers.
• Former President of Jilin Provincial Cancer Hospital.
• Awarded the National Famous Doctor honor for outstanding contributions to oncology.
• Holds leadership roles in the Chinese Anti-Cancer Association particle therapy committee.

Professor and Chief Physician. Director of Gynecologic Oncology. PhD in Gynecologic Oncology from the Cancer Hospital, Chinese Academy of Medical Sciences. MSc in Obstetrics and Gynecology from Peking Union Medical College Hospital. Nearly 30 years of clinical experience. Published in SCI and core journals. Co‑author of two gynecologic oncology monographs.

Specializes in standardized diagnosis and comprehensive treatment of ovarian, cervical, and endometrial cancers. Provides surgery, chemotherapy, targeted therapy, immunotherapy, and intraperitoneal hyperthermic perfusion. Pioneer of single‑port laparoscopy at her hospital. Also performs multi‑port laparoscopy, open surgery, and hysteroscopic procedures for benign gynecologic disease.

Affiliations: Youth Director, Chinese Anti‑Cancer Association. Youth Member, Gynecologic Oncology Committee, Fujian Anti‑Cancer Association. Member, Peritoneal Tumor Committee, Fujian Anti‑Cancer Association. Youth Member, Obstetrics and Gynecology Committee, Fujian Medical Association.

Dr. Li Huaifang specializes in gynecologic tumors, pelvic floor disorders, and minimally invasive gynecologic surgery. She has performed over 10,000 minimally invasive procedures and more than 5,000 pelvic floor repairs. Her work includes laparoscopic and hysteroscopic cancer operations. She also performs reconstructive surgery for prolapse and incontinence. She has demonstrated surgical techniques at national conferences.

Academic roles: National member, Pelvic Floor Dysfunction Group (CMA OBGYN). Deputy head, Shanghai MA OBGYN Pelvic Floor Group. Expert, Shanghai Gynecologic Quality Control Panel. She joined the 12th Five-Year Plan. She now leads a 14th Five-Year Plan sub-project on degradable pelvic floor meshes. Publications: 240+ papers, including 50+ SCI. Textbook co-author and supervisor at Tongji University with 50+ mentees. Honors include the Shanghai Medical S&T Award, the Chinese MCH S&T Award, and prizes for pelvic floor reconstruction in 2006, 2012, and 2015.